Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taselisib in PI3K-positive squamous cell lung cancer (Lung-MAP Sub-Study)
NCT02785913Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of taselisib / pictilisib in squamous cell carcinoma of the lung (LSCC) (3 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Objective Response Rate at 3 years. Started Nov 2014; status: completed.
02
Drugs
taselisib / pictilisib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT02785913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02785913.